NEW DELHI: Bharat Biotech’s Covaxin vaccine has shown 78% interim efficacy against the coronavirus, as per the result from phase 3 trials.
The vaccine has also demonstrated 100% efficacy against severe Covid-19.
Covaxin had earlier demonstrated an 81% efficacy in preventing Covid-19 after the second dose, as per the interim results of Phase III trials made public by its developer Bharat Biotech.
The company had said the first interim analysis is based on 43 cases of Covid-19, of which 36 cases were observed in the group of volunteers that received the placebo as against 7 cases observed in volunteers who got the two doses of Covaxin, resulting in an efficacy of 80.6%.
The vaccine has also demonstrated 100% efficacy against severe Covid-19.
Covaxin had earlier demonstrated an 81% efficacy in preventing Covid-19 after the second dose, as per the interim results of Phase III trials made public by its developer Bharat Biotech.
The company had said the first interim analysis is based on 43 cases of Covid-19, of which 36 cases were observed in the group of volunteers that received the placebo as against 7 cases observed in volunteers who got the two doses of Covaxin, resulting in an efficacy of 80.6%.
